Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC).

被引：0
|
作者：
Conteduca, Vincenza
Scarpi, Emanuela
Wetterskog, Daniel
Ferroni, Fabio
Rossi, Alice
Romanel, Alessandro
Gurioli, Giorgia
Bleve, Sara
Gianni, Caterina
Brighi, Nicole
Schepisi, Giuseppe
Lolli, Cristian
Cortesi, Pietro
Barone, Domenico
Demichelis, Francesca
Paganelli, Giovanni
Beltran, Himisha
Attard, Gerhardt
De Giorgi, Ugo
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Meldola, MA, Italy
[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Unit Biostat & Clin Trials, Meldola, Italy
[3] UCL Canc Inst, London, England
[4] Ist Sci Romagnolo Studio & Cura Tumori Dino Amado, Meldola, Italy
[5] IRST IRCCS, Meldola, Italy
[6] Univ Trento, Trento, Italy
[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[8] City Hosp, Dept Oncol, Rimini, Italy
[9] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[10] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy
[11] Sci Inst Romagna Study & Treatment Tumors IRST, UOC Nucl Med, Meldola, Italy
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
[13] UCL, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5048
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
    Conteduca, Vincenza
    Scarpi, Emanuela
    Wetterskog, Daniel
    Brighi, Nicole
    Ferroni, Fabio
    Rossi, Alice
    Romanel, Alessandro
    Gurioli, Giorgia
    Bleve, Sara
    Gianni, Caterina
    Schepisi, Giuseppe
    Lolli, Cristian
    Cortesi, Pietro
    Matteucci, Federica
    Barone, Domenico
    Paganelli, Giovanni
    Demichelis, Francesca
    Beltran, Himisha
    Attard, Gerhardt
    De Giorgi, Ugo
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (07) : 1166 - 1173
  • [2] Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)
    Patel, Jai N.
    Jiang, Chen
    Hertz, Daniel L.
    Mulkey, Flora A.
    Friedman, Paula N.
    Halabi, Susan
    Ratain, Mark J.
    Morris, Michael J.
    Small, Eric J.
    Owzar, Kouros
    Kelly, William K.
    McLeod, Howard L.
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Increased risk of venous thromboembolism (VTE) and shorter survival in neuroendocrine versus castration-resistant prostate cancer
    Jakubowski, C.
    Vlachostergios, P. J.
    Christos, P.
    Nanus, D. M.
    Beltran, H.
    Tagawa, S. T.
    THROMBOSIS RESEARCH, 2018, 164 : S214 - S214
  • [4] Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
    Conteduca, V.
    Scarpi, E.
    Wetterskog, D.
    Brighi, N.
    Schepisi, G.
    Romanel, A.
    Casadei, C.
    Lolli, C.
    Gurioli, G.
    Toma, I.
    Poti, G.
    Farolfi, A.
    Demichelis, F.
    Attard, G.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2021, 32 : S633 - S633
  • [5] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafeiris
    Mateo, Joaquin
    De Bono, Johann S.
    LABORATORY INVESTIGATION, 2016, 96 : 251A - 251A
  • [7] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafetris
    Mateo, Joaquin
    De Bono, Johann S.
    MODERN PATHOLOGY, 2016, 29 : 251A - 251A
  • [8] Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Scarpi, Emanuela
    Rossi, Alice
    Ferroni, Fabio
    Gurioli, Giorgia
    Bleve, Sara
    Gianni, Caterina
    Schepisi, Giuseppe
    Brighi, Nicole
    Lolli, Cristian
    Cursano, Maria Concetta
    Virga, Alessandra
    Casadei, Chiara
    Altavilla, Amelia
    Farolfi, Alberto
    Ulivi, Paola
    Barone, Domenico
    Matteucci, Federica
    Paganelli, Giovanni
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Annala, Matti
    Beja, Kevin
    Vandekerkhove, Gillian
    Zulfiqar, Muhammad
    Finch, Daygen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
12345